Compass Therapeutics, Inc (CMPX) insider trading

Every open-market stock purchase and sale by Compass Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • No open-market insider trades in the last 12 months.
  • Last insider buy: Jonathan Anderman (General Counsel), $47.3K, 5 months ago.

Last 12 months: insiders bought $75.6K (2 buys) and sold $0 (0 sales).

Recent CMPX insider trades

DateInsiderTradeValue
Apr 29, 2026Jonathan Anderman (General Counsel)Bought (not open market)$47.3K
Apr 29, 2026Jonathan Anderman (General Counsel)Bought$47.3K
Apr 29, 2026Neil Lerner (C-suite exec)Bought (not open market)$28.4K
Apr 29, 2026Neil Lerner (C-suite exec)Bought$28.4K
Feb 8, 2026Thomas J. Schuetz (CEO)Sold (not open market)$239K
Jan 9, 2026Thomas J. Schuetz (CEO)Sold (not open market)$250K
Jan 2, 2026Thomas J. Schuetz (CEO)Bought (not open market)$1.3M
Jan 2, 2026Jonathan Anderman (General Counsel)Bought (not open market)$776K
Jan 2, 2026Barry Shin (CFO)Bought (not open market)$646K
Jan 2, 2026Neil Lerner (C-suite exec)Bought (not open market)$323K
Jan 2, 2026James P Boylan (Director)Bought (not open market)—
Jan 2, 2026Mary Ann Gray (Director)Bought (not open market)—
Jan 2, 2026Neil Lerner (C-suite exec)Bought (not open market)—
Jan 2, 2026Jonathan Anderman (General Counsel)Bought (not open market)—
Jan 2, 2026Ellen Chiniara (Director)Bought (not open market)—
Jan 2, 2026Richard S Lindahl (Director)Bought (not open market)—
Jan 2, 2026Philip Ferneau (Director)Bought (not open market)—
Jan 2, 2026Carl L Gordon (Director)Bought (not open market)—
Jan 2, 2026Cynthia Sirard (C-suite exec)Bought (not open market)—
Jan 2, 2026Barry Shin (CFO)Bought (not open market)—
Jan 2, 2026Thomas J. Schuetz (CEO)Bought (not open market)—
Jan 2, 2026Arjun Prasad (C-suite exec)Bought (not open market)—
Nov 16, 2025Thomas J. Schuetz (CEO)Sold (not open market)$213K

Who's trading CMPX

Get free alerts when an insider at Compass Therapeutics, Inc files a new trade →